Table 1.
Clinical findings of two groups
| Characteristic | DEB-TACE group | PVA-TACE group | P-value |
|---|---|---|---|
|
| |||
| Age (years) | 52.8±9.9 | 54.3±12.0 | 0.617 |
| Sex (male/female, %) | 22/4, 84.6/15.4 | 27/5, 84.4/15.6 | 1.000 |
| Tumor size (mm) | 97.2±38.2 | 108.1±59.0 | 0.421 |
| Albumin (g/L) | 34.2±3.5 | 35.8±3.9 | 0.114 |
| Bilirubin (umol/L) | 17.8±7.7 | 17.3±9.2 | 0.854 |
| Child–Pugh class (A/B, %) | 20/6, 76.9/23.1 | 21/11, 65.6/34.4 | 0.347 |
| PVTT (yes/no, %) | 12/14, 46.1/53.9 | 13/19, 40.6/59.4 | 0.672 |
| Ascites (yes/no, %) | 5/21, 19.2/80.8 | 10/22, 31.2/68.8 | 0.299 |
| APS grading (1/2/3, %) | 12/10/4, 46.1/38.5/15.4 | 11/15/6, 34.4/46.9/18.7 | 0.730 |
| BCLC staging (B/C, %) | 13/13, 50.0/50.0 | 15/17, 46.9/53.1 | 0.813 |
| ECOG ps (0/1/2, %) | 7/17/2, 26.9/65.4/7.7 | 10/16/6, 31.2/50.0/18.8 | 0.400 |
| Distant metastasis (yes/no, %) | 2/24, 7.7/92.3 | 6/26, 18.7/81.3 | 0.205 |
Abbreviations: APS, arterioportal shunt; BCLC, Barcelona Clinic Liver Cancer; DEB-TACE, transarterial chemoembolization with drug-eluting beads; ECOG ps, Eastern Cooperative Oncology Group performance status; PVA-TACE, polyvinyl alcohol plus transarterial chemoembolization; PVTT, portal vein tumor thrombus.